Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53–Mutant NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53 Mutant NSCLC via Noxa Expression
Clin. Cancer Res 2020 Dec 11;[EPub Ahead of Print], A Tanimoto, S Matsumoto, S Takeuchi, S Arai, K Fukuda, A Nishiyama, K Yoh, T Ikeda, N Furuya, K Nishino, Y Ohe, K Goto, S YanoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.